The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC

OBJECTIVE: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs: sorafenib, lenvatinib, and apatinib) plus camrelizumab (TACE-TKIs-C) vs TACE combined with TKIs (TACE-TKIs) for advanced hepatocellular carcinoma (HCC). METHODS: I...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Tao, Ren, Yanqiao, Sun, Bo, Chen, Lei, Zhu, Licheng, Zhang, Lijie, Zheng, Chuansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028391/
https://www.ncbi.nlm.nih.gov/pubmed/36960308
http://dx.doi.org/10.2147/JHC.S400948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028391/
https://www.ncbi.nlm.nih.gov/pubmed/36960308
http://dx.doi.org/10.2147/JHC.S400948

Ejemplares similares